Christian Bruehlmann has been Chief Strategy Officer since December 2023. He was CBO and co-founder of Proteomedix AG, a Swiss healthcare company whose mission is to transform prostate cancer diagnosis, which was acquired by the Company in December 2023. Mr. Bruehlmann gained 20 years of experience in public and private companies in the life sciences, information and communications (ICT) and financial industries. Being responsible for product management, business development, operations and finance, he was instrumental in Proteomedix’ development from inception to the market introduction of the lead product Proclarix, a blood based prostate cancer test panel and risk score currently available in Europe and exclusively out-licensed to LabCorp for the US. Previously, he worked for Swisscom, Switzerland's telecom market leader in several strategic and leadership roles in the area of digitalization. Mr. Bruehlmann received his Bachelor and Master in Business Administration from University of Zurich, Switzerland and completed executive professional trainings at the Babson College, USA and at the University of St. Gallen, Switzerland.
Dr. Ralph Schiess
Chief Science Officer and Interim Chief Executive Officer
Dr. Ralph Schiess has been Chief Science Officer since December 2023 and Interim Chief Executive Officer since January 2024. Dr. Schiess worked for 10 years in world-class academic institutions both in the US and Europe and gained over 10 years of experience in the diagnostic industry successfully developing products from scientific prototypes to commercial products. Dr. Schiess was CEO and co-founder of Proteomedix AG, a Swiss healthcare company with the mission to transform prostate cancer diagnosis, which was acquired by the Company in December 2023. Under his guidance, Proteomedix identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product, Proclarix, is a blood-based prostate cancer test panel and risk score currently available in Europe and exclusively out-licensed to LabCorp for the US. Proclarix was recently included in both the American and European Urology guidelines. Dr. Schiess received his M.S. from the University of Zurich, followed by an internship at the Institute of System Biology in Seattle. Thereafter, he received a doctorate from the Swiss Federal Institute of Technology.
Chief Strategy Officer
Chief Financial Officer
Bruce Harmon has been the Chief Financial Officer since October 2023. Mr. Harmon has over 40 years of experience as a financial professional, with more than 30 years serving as a controller, chief financial officer, director, audit chairman, and as a consultant providing CFO services primarily to publicly traded companies. Mr. Harmon has served as CFO of Marizyme, Inc. from 2020 through 2021, as CFO of bioAffinity Technologies, Inc. in 2022, a director for Dale Biotech LLC since 2017, and as a director of Patriax Industries™ since 2023. Mr. Harmon has, through his consulting firm, Lakeport Business Services, Inc., worked with numerous clients since 2008, primarily providing CFO services. Mr. Harmon has extensive experience with fund raising, mergers and acquisitions, and turnarounds. Mr. Harmon has been a key person in the public registration of 15 companies, including an IPO to NASDAQ, and four life sciences companies. Mr. Harmon was part of a three-person team that, at the invitation of the Environmental Programmé, presented a green building product to delegates at the United Nations in 2008. Mr. Harmon has an accounting degree from Missouri State University, 1979.